SB-300, Jaguar’s Drug Product Candidate for the Treatment of Gastric Ulcers, Enables Continued Therapy in Performance Horses in Accordance with Standard Testing Guidelines
Results of Initial Study Show that Jaguar’s Equine Product Candidate for Treatment of Gastric Ulcers May Offer Horse Owners an Additional Advantage in the Competition Horse World, where Requirements Exist for Animals to Compete Free from the Effect of Any Drugs
Jaguar believes the results of this exploratory study are an important step towards development of a product that treats EGUS without interfering with the animals’ competition schedules. In addition, the Company believes confirmation of no withdrawal time prior to competition should give SB-300 a remarkable advantage over other products that address EGUS that are currently on the market. Future work is being planned to confirm these results. The study also provided visual evidence that feed does not appear to interfere with the product candidate’s local availability in the gut.
As Jaguar announced on
“SB-300 is a product that acts locally in the gut with minimal systemic
absorption, and we expected that the drug test would not detect any
substances commonly disallowed by horse racing authorities. We are
excited about a new potential approach to the treatment of equine
ulcers, and anticipate confirming these results with longer duration of
product administration in our upcoming studies in 2016,” said
Data from the
For more information, please visit www.jaguaranimalhealth.com.
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s belief that SB-300 may provide horse owners with an additional advantage in the competition horse world, the Company’s belief that the results of this exploratory initial study are a significant step towards providing horse owners with a product that may treat gastric ulcers without interfering with their competition schedule, Jaguar’s belief that confirmation of a zero-day withdrawal prior to competition should give SB-300 a remarkable advantage over competitor products that address EGUS that are currently on the market, Jaguar’s belief that upcoming studies in 2016 will confirm the results of this exploratory study with longer product administration, Jaguar’s intention to develop formulations of SB-300 in horses and species-specific formulations of Neonorm™ in additional target species, and the Company’s plan to develop formulations of Canalevia™ for cats and dogs. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
1Pellegrini FL. Results of a large-scale necroscopic study of equine colonic ulcers. J Equine Vet Sci. 2005;25(3):113-117.